These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

343 related items for PubMed ID: 21276715

  • 1. Strategies to overcome extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases in shigellae.
    Livermore DM, Mushtaq S, Nguyen T, Warner M.
    Int J Antimicrob Agents; 2011 May; 37(5):405-9. PubMed ID: 21276715
    [Abstract] [Full Text] [Related]

  • 2. Activity of faropenem against cephalosporin-resistant Enterobacteriaceae.
    Mushtaq S, Hope R, Warner M, Livermore DM.
    J Antimicrob Chemother; 2007 May; 59(5):1025-30. PubMed ID: 17353220
    [Abstract] [Full Text] [Related]

  • 3. [Mechanisms of resistance in Enterobacteriaceae towards beta-lactamase antibiotics].
    Susić E.
    Acta Med Croatica; 2004 May; 58(4):307-12. PubMed ID: 15700687
    [Abstract] [Full Text] [Related]

  • 4. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
    Mushtaq S, Warner M, Ge Y, Kaniga K, Livermore DM.
    J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
    [Abstract] [Full Text] [Related]

  • 5. Cefepime and the inoculum effect in tests with Klebsiella pneumoniae producing plasmid-mediated AmpC-type beta-lactamase.
    Kang CI, Pai H, Kim SH, Kim HB, Kim EC, Oh MD, Choe KW.
    J Antimicrob Chemother; 2004 Dec; 54(6):1130-3. PubMed ID: 15486080
    [Abstract] [Full Text] [Related]

  • 6. Mecillinam/clavulanate combination: a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
    Lampri N, Galani I, Poulakou G, Katsarolis I, Petrikkos G, Giamarellou H, Souli M.
    J Antimicrob Chemother; 2012 Oct; 67(10):2424-8. PubMed ID: 22665388
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Extended spectrum AmpC and metallo-beta-lactamases in Serratia and Citrobacter spp. in a disc approximation assay.
    Rizvi M, Fatima N, Rashid M, Shukla I, Malik A, Usman A, Siddiqui S.
    J Infect Dev Ctries; 2009 Apr 30; 3(3):177-86. PubMed ID: 19759472
    [Abstract] [Full Text] [Related]

  • 10. Extended spectrum AmpC and metallo-beta-lactamases in Serratia and Citrobacter spp. in a disc approximation assay.
    Rizvi M, Fatima N, Rashid M, Shukla I, Malik A, Usman A, Siddiqui S.
    J Infect Dev Ctries; 2009 May 01; 3(4):285-94. PubMed ID: 19759492
    [Abstract] [Full Text] [Related]

  • 11. In vivo selection of Enterobacter aerogenes with reduced susceptibility to cefepime and carbapenems associated with decreased expression of a 40 kDa outer membrane protein and hyperproduction of AmpC beta-lactamase.
    Fernández-Cuenca F, Rodríguez-Martínez JM, Martínez-Martínez L, Pascual A.
    Int J Antimicrob Agents; 2006 Jun 01; 27(6):549-52. PubMed ID: 16697150
    [Abstract] [Full Text] [Related]

  • 12. Transconjugation and genotyping of the plasmid-mediated AmpC beta-lactamase and extended-spectrum beta-lactamase genes in Klebsiella pneumoniae.
    Shi WF, Zhou J, Qin JP.
    Chin Med J (Engl); 2009 May 05; 122(9):1092-6. PubMed ID: 19493446
    [Abstract] [Full Text] [Related]

  • 13. Bactericidal activity of oral beta-lactam antibiotics in plasma and urine versus isogenic Escherichia coli strains producing broad- and extended-spectrum beta-lactamases.
    Bedenic B, Vranes J, Suto S, Zagar Z.
    Int J Antimicrob Agents; 2005 Jun 05; 25(6):479-87. PubMed ID: 15894465
    [Abstract] [Full Text] [Related]

  • 14. Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model.
    Zhanel GG, Baudry PJ, Tailor F, Cox L, Hoban DJ, Karlowsky JA.
    J Antimicrob Chemother; 2009 Oct 05; 64(4):824-8. PubMed ID: 19643776
    [Abstract] [Full Text] [Related]

  • 15. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases.
    Calbo E, Romaní V, Xercavins M, Gómez L, Vidal CG, Quintana S, Vila J, Garau J.
    J Antimicrob Chemother; 2006 Apr 05; 57(4):780-3. PubMed ID: 16492721
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Orthodox and unorthodox clavulanate combinations against extended-spectrum beta-lactamase producers.
    Livermore DM, Hope R, Mushtaq S, Warner M.
    Clin Microbiol Infect; 2008 Jan 05; 14 Suppl 1():189-93. PubMed ID: 18154546
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.